These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1283185)

  • 1. Pharmacokinetics of nilvadipine.
    von Nieciecki A; Huber HJ; Stanislaus F
    J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S22-9. PubMed ID: 1283185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nilvadipine: profile of a new calcium antagonist. An overview.
    Rosenthal J
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S92-107. PubMed ID: 7898101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption, distribution and excretion of nilvadipine, a new dihydropyridine calcium antagonist, in rats and dogs.
    Tokuma Y; Fujiwara T; Noguchi H
    Xenobiotica; 1987 Nov; 17(11):1341-9. PubMed ID: 3433803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of (+)- and (-)-nilvadipine after oral dosing with racemic (+)-nilvadipine in man.
    Tokuma Y; Fujiwara T; Noguchi H
    Res Commun Chem Pathol Pharmacol; 1987 Aug; 57(2):229-37. PubMed ID: 3659571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nilvadipine in hypertension with renal dysfunction.
    Berger HH; Albert FW
    J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S73-9. PubMed ID: 1283194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 24-hour blood pressure control after single daily doses of nivaldipine in patients with essential hypertension.
    Lossnitzer K; Huber HJ; Kuchlbauer R; Quitzdorff G
    J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S35-42. PubMed ID: 1283187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties.
    Herbette LG; Vecchiarelli M; Sartani A; Leonardi A
    Blood Press Suppl; 1998; 2():10-7. PubMed ID: 9850437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of barnidipine hydrochloride, a new dihydropyridine calcium channel blocker, in the rat, dog and human.
    Teramura T; Watanabe T; Higuchi S; Hashimoto K
    Xenobiotica; 1995 Nov; 25(11):1237-46. PubMed ID: 8592872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of mebudipine, a new calcium antagonist, following single intravenous and oral administrations in rats.
    Bohlooli S; Keyhanfar F; Mahmoudian M
    Biopharm Drug Dispos; 2004 May; 25(4):187-91. PubMed ID: 15108221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of vasodilators. Part I.
    Kirsten R; Nelson K; Kirsten D; Heintz B
    Clin Pharmacokinet; 1998 Jun; 34(6):457-82. PubMed ID: 9646008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between the pharmacokinetic and pharmacodynamic profile of nilvadipine in the dog.
    Wu WH; Henderson BM; Lanc R; Garnes D; Yacobi A; Silber BM
    Drug Metab Dispos; 1988; 16(2):222-7. PubMed ID: 2898337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benidipine hydrochloride--a new calcium-channel blocker of the dihydropyridine type. Pharmacokinetics, pharmacodynamics, tolerance and dose finding in mild to moderate hypertension.
    Maier-Lenz H; Rode H; Lenau H; Thieme G; Wölke E; Kobayashi H; Kobayashi S; Oka T
    Arzneimittelforschung; 1988 Nov; 38(11A):1757-63. PubMed ID: 3219156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of nilvadipine and amlodipine in patients with mild to moderate essential hypertension: a double blind, prospective, randomised clinical trial.
    Leonetti G;
    Curr Med Res Opin; 2005 Jun; 21(6):951-8. PubMed ID: 15969895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amlodipine: a once daily calcium antagonist.
    Burges RA
    J Hum Hypertens; 1991 Aug; 5 Suppl 1():49-54. PubMed ID: 1834846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
    Perucca E; Cloyd J; Critchley D; Fuseau E
    Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of nilvadipine after single oral doses in healthy volunteers.
    Cheung WK; Woodward DL; Shin K; Hibberd M; Pearse S; Desjardins RE; Yacobi A; Silber BM
    Int J Clin Pharmacol Res; 1988; 8(5):299-305. PubMed ID: 3229870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of small intestinal cytochromes p450 in the bioavailability of oral nifedipine.
    Zhang QY; Kaminsky LS; Dunbar D; Zhang J; Ding X
    Drug Metab Dispos; 2007 Sep; 35(9):1617-23. PubMed ID: 17567730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of nisoldipine. I. Absorption, concentration in plasma, and excretion after single administration of [14C]nisoldipine in rats, dogs, monkey, and swine.
    Ahr HJ; Krause HP; Siefert HM; Suwelack D; Weber H
    Arzneimittelforschung; 1988 Aug; 38(8):1093-8. PubMed ID: 3196402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nilvadipine. A review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina.
    Brogden RN; McTavish D
    Drugs Aging; 1995 Feb; 6(2):150-71. PubMed ID: 7711361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.